Min Ren
Eisai Inc., Woodcliff Lake, NJAuthored Items
December 16, 2021 | December 2021 Vol 12, No 12
Krysten Soldan, RN, Carolyn Johns, NP, Matthew H. Taylor, MD, Kathryn Gillis, PharmD, Robert Orlowski, MD, Min Ren, Vicky Makker
November 13, 2020 | November 2020 Vol 11, No 11
Lenvatinib plus pembrolizumab demonstrated promising antitumor activity in endometrial carcinoma (EC) in a phase 1b/2 clinical trial (Study 111/KEYNOTE-146).
Last modified: December 17, 2021